Nicotine Products: A Pharmacokinetic Risk Underrecognized

Derek Yach, World Nicotine Congress, Brussels 2026

Nicotine harm-reduction initiatives are reshaping global tobacco control strategies. The introduction of vapes, heated tobacco products, nicotine pouches, and nicotine replacement therapies (NRTs) now supports millions in their efforts to quit smoking. In addition to mitigating the health risks associated with combustion, recent evidence suggests that nicotine itself may confer direct benefits, including enhancements in cognitive function, mood regulation, and neuroprotection under select clinical circumstances.

Nonetheless, among former smokers living with chronic conditions—such as schizophrenia, epilepsy, or chronic obstructive pulmonary disease—the transition from combustible cigarettes to clean nicotine delivery presents a less widely recognized but clinically meaningful pharmacokinetic risk. Eliminating combustion prompts a rapid normalization of key metabolic pathways, most notably the CYP1A2 enzyme system, which can alter drug metabolism substantially—occasionally resulting in plasma concentrations doubling within days.

Mechanistic Considerations

Combustible cigarette smoke contains polycyclic aromatic hydrocarbons (PAHs), known to induce hepatic cytochrome P450 enzymes. Unlike cigarette smoke, nicotine delivered through vaping or NRT does not maintain this induction. Consequently, cessation of smoking leads to normalization of hepatic enzyme activity within approximately one week. Drugs metabolized via CYP1A2—including clozapine, olanzapine, theophylline, and phenytoin—may subsequently accumulate to higher levels, potentially escalating toxicity risks unless therapeutic dosing is promptly adjusted.

Clinical Examples

For individuals diagnosed with schizophrenia, rates of cigarette smoking approach 90 percent. Upon cessation, clozapine plasma levels may increase by over 70 percent within one week, predisposing patients to adverse effects such as sedation or seizures. Olanzapine exhibits similar challenges, yet adjustment of psychiatric medication dosages in response to smoking restrictions or cessation remains inconsistent in many healthcare settings.

Patients with COPD face analogous risks; following smoking cessation, the clearance of theophylline may be reduced by up to half, heightening the possibility of cardiac arrhythmias or seizures. Tuberculosis treatment further complicates the scenario: rifampicin induces several metabolic enzymes, and the presence of smoke-related induction can magnify these effects. Discontinuation of smoking during rifampicin therapy may unexpectedly elevate serum concentrations of concomitant medications.

Regulatory Considerations

While several national regulatory bodies—including the UK MHRA, Australia’s TGA, and the US FDA—recognize these metabolic changes, there remains a lack of international alignment. Neither the WHO nor ICH has established harmonized protocols linking smoking cessation, NRT, or vaping to explicit dose-adjustment recommendations. This absence creates uncertainty for clinicians, particularly amidst the widespread adoption of alternative nicotine products and smoke-free policies worldwide.

Integrating Pharmacotherapy With Harm Reduction

Effective public health policy requires the integration of harm reduction and contemporary pharmacotherapy. It is imperative that hospital electronic prescribing systems automatically prompt clinical review of medications metabolized by CYP1A2 whenever a patient's smoking status is updated to "former smoker." Pharmacovigilance systems should also flag “recent smoking cessation” as a relevant factor in reports of adverse drug reactions.

Incorporation of dose-adjustment guidance into the WHO Essential Medicines List and standardized labeling across regulatory authorities would mitigate preventable morbidity. Professional education programs—in psychiatry, pulmonology, infectious diseases, and pharmacy—should emphasize that while nicotine replacement sustains dependence management, it does not perpetuate enzyme induction.

Conclusion

Tobacco combustion products, rather than nicotine itself, are responsible for CYP1A2 induction. When individuals discontinue smoking—even if nicotine consumption continues through non-combustible sources—hepatic metabolism decelerates and plasma drug levels may rise. Anticipating and adjusting for these pharmacokinetic shifts is critical to safeguarding patient safety and upholding the integrity of tobacco harm-reduction interventions.

As the global community strives for a smoke-free future, the establishment of cohesive guidelines integrating both harm-reduction and therapeutic considerations of nicotine use is not only judicious—it is fundamental to advancing global health.